12:00 AM
Jun 22, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lestaurtinib: Preliminary Phase II data

Top-line data from an open-label, international, pivotal Phase II trial in 224 patients with relapsed AML expressing FLT3-activating mutations showed that lestaurtinib plus chemotherapy missed the primary endpoint of improving complete remission rate vs....

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >